ESR1 and breast cancer: Increased prevalence of function-affecting mutations in tumor suppressor TP53, in DDR-related genes, and in genes encoded for other proteins of the PI3K/AKT pathway besides PIK3CA may be causally involved in the pathogenesis of additional cases of ER-positive/HER2-negative breast cancers with high mutation counts.